Federal grants to Alpenglow Biosciences, Inc.
Alpenglow Biosciences, Inc. in Seattle, Washington received $3.0 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Cancer Detection and Diagnosis Research, with $2.4 million. In fiscal 2025 it was awarded $1.1 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$3.0 million
- Awards4
- Awarded in FY 2025$1.1 million
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $667,656 |
| FY 2022 | 1 | $252,522 |
| FY 2023 | 0 | $0 |
| FY 2024 | 1 | $994,325 |
| FY 2025 | 1 | $1.1 million |
Programs that fund Alpenglow Biosciences, Inc.
| Program | Awards | Amount |
|---|---|---|
| Cancer Detection and Diagnosis Research | 2 | $2.4 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 2 | $521,831 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $3.0 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| 3D spatial biology of prostate cancer biopsies for earlier identification of high risk patients - abstract prostate cancer is a curable disease when treated early before metastases occur. Current diagnostic methods struggle to accurately predict which patients will develop metastases, resulting in t | Cancer Detection and Diagnosis Research | July 9, 2024 | $2.0 million |
| Same-day breast pathology results using open-top light-sheet microscopy for image-guided core needle biopsies - abstract (300 words maximum) each year, over 700 women undergo an image-guided core needle biopsy (CNB) to evaluate a suspicious breast finding at the seattle cancer care alliance, with on | Cancer Detection and Diagnosis Research | June 25, 2021 | $398,302 |
| 3D quantification of nash-related liver fibrosis using open-top light-sheet microscopy - abstract non-alcoholic fatty liver disease (NAFLD) prevalence is estimated at >25% in the U.S., making it the most common cause of chronic liver disease. Non-alcoholic steatohepatitis (NASH), the progressive for | Diabetes, Digestive, and Kidney Diseases Extramural Research | September 17, 2021 | $269,314 |
| 3D diagnosis of hirschsprung disease using open-top light-sheet microscopy - abstract hirschsprung disease is a congenital defect that affects an estimated 1:5000 liveborn infants. It is characterized by absent ganglion cells (neurons) in the distal rectum and a variable length of contiguous proxima | Diabetes, Digestive, and Kidney Diseases Extramural Research | March 31, 2022 | $252,516 |
Questions people ask
How much federal grant money does Alpenglow Biosciences, Inc. get?
$3.0 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Alpenglow Biosciences, Inc. the most?
The Department of Health and Human Services, with $3.0 million in 4 awards.
What is Alpenglow Biosciences, Inc.'s largest federal grant?
$2.0 million under Cancer Detection and Diagnosis Research, with its first action in the period on July 9, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Alpenglow Biosciences, Inc.?
Its largest are Cancer Detection and Diagnosis Research and Diabetes, Digestive, and Kidney Diseases Extramural Research.
Other grant recipients in Seattle
- University of Washington
- Central Puget Sound Regional Transit Authority
- Fred Hutchinson Cancer Center
- King County Metro Transit
- Port of Seattle
- Seattle Children's Hospital
- Allen Institute
- Seattle Housing Authority
Largest federal grant recipients in Washington · Federal grants in Washington